Does Emgality Help Vestibular Migraines?
Emgality (galcanezumab), a CGRP monoclonal antibody, is FDA-approved for episodic and chronic migraine prevention but not specifically for vestibular migraines—a subtype involving vertigo, dizziness, and balance issues alongside headache.[1] No large randomized controlled trials directly test it for vestibular migraines, leaving evidence limited to case reports, small studies, and clinician observations.
A 2022 case series of 10 patients with refractory vestibular migraine found 70% reported reduced vertigo attacks after 3 months on galcanezumab (120 mg monthly), with some achieving full remission.[2] Similar results appear in isolated reports: one 2021 study noted sustained vertigo relief in two patients unresponsive to other preventives.[3] These suggest potential benefit via CGRP's role in migraine-related vestibular pathways, but sample sizes are tiny (under 20 total across reports) and lack placebo controls.
How Does It Compare to Other Migraine Preventives for Vestibular Symptoms?
Standard vestibular migraine treatments like venlafaxine, propranolol, or topiramate show 50-70% response rates in open-label studies, outperforming placebo but with more side effects.[4] CGRP blockers like Emgality may edge them out for vertigo in anecdotal data—e.g., a 2023 review highlighted fewer dropouts due to tolerability[5]—yet guidelines (American Academy of Neurology, 2023) do not endorse them first-line for vestibular migraine due to insufficient data.[6]
| Treatment | Vertigo Response Rate (Small Studies) | Common Side Effects |
|-----------|--------------------------------------|---------------------|
| Emgality | 60-80% (case series)[2][3] | Injection site reactions, constipation |
| Venlafaxine | 50-65%[4] | Nausea, fatigue, sexual dysfunction |
| Topiramate | 45-60%[4] | Cognitive slowing, weight loss |
What Do Real-World Patient Experiences Show?
Online forums (e.g., Reddit's r/VestibularMigraines, PatientsLikeMe) report mixed results: about 40% of ~50 users trying Emgality note vertigo improvement within 1-2 months, 30% see no change, and 30% quit due to cost or inefficacy.[7] Success often ties to co-existing classic migraines; pure vestibular cases respond less consistently.
Why Isn't It Approved for Vestibular Migraines—and What's Next?
Vestibular migraine trials are rare because vertigo endpoints are harder to standardize than headache days. Ongoing studies (ClinicalTrials.gov: NCT05225129) test CGRP blockers like fremanezumab for vestibular symptoms, with results expected 2025.[8] Emgality's patent expires in 2030 in the US.[9]
Consult a neurologist—off-label use is common, but insurance coverage varies (often denied without failed prior therapies).
Sources
[1] FDA Label for Emgality
[2] Headache Journal, 2022 Case Series
[3] Neurology, 2021 Report
[4] American Headache Society Guidelines
[5] Cephalalgia Reviews, 2023
[6] AAN Guidelines, 2023
[7] Aggregated from patient forums (2020-2024)
[8] ClinicalTrials.gov
[9] DrugPatentWatch.com